Affimed Reports First Quarter 2022 Financial Results and Highlights Recent Operational Progress
Affimed N.V. (Nasdaq: AFMD) reported its first quarter 2022 financial results and clinical updates. The REDIRECT study for AFM13 monotherapy completed enrollment, with topline data expected in Q4 2022. At AACR 2022, AFM13 showed a 100% objective response rate and a rise in complete responses. The cash position is strong, with €257.5 million expected to support operations into mid-2024. However, net loss for Q1 2022 was €16.7 million, down from a profit a year ago, while R&D expenses surged by 61% to €18.4 million, indicating increased investment in their product pipeline.
- 100% objective response rate reported for AFM13 in combination with NK cells.
- Topline data from REDIRECT study expected in Q4 2022.
- Cash runway extended into mid-2024 following a public offering.
- Net loss of €16.7 million in Q1 2022, a significant decline from €1.4 million profit in Q1 2021.
- 61% increase in R&D expenses to €18.4 million, reflecting higher development costs.
- AFM13 monotherapy: Completed enrollment in the REDIRECT study for patients with relapsed or refractory PTCL; on track to report topline data in the fourth quarter of 2022
- AFM13 combination with NK cells: Reported data at AACR 2022 showing a
100% objective response rate (ORR) and an increase in complete responses (CR) from38% , reported in December, to62% after a second cycle of therapy in 13 patients at the recommended phase 2 dose (RP2D) with encouraging signals on durability - AFM24 monotherapy: Completed enrollment of the 720mg cohort; presented data at AACR 2022 and NK2022; data show a plateau in NK cell activation and CD16 receptor binding and confirm 480mg as the RP2D
- AFM24 combination studies with NK cells and anti PD-L1 checkpoint inhibitor: Continued enrollment of patients in two separate phase 1/2a studies investigating AFM24 in combination with atezolizumab and SNK01 NK cells
- AFM28 monotherapy: On track for IND filing in relapsed/refractory AML in June 2022; initiation of phase 1 clinical trial expected in the second half of 2022
- AFM28 combination with NK cells: Presented a poster of preclinical data at NK2022 demonstrating that AFM28 exhibits greater surface retention than conventional monoclonal antibodies and lysis of CD123-positive tumor cells when pre-complexed or co-administered with cryopreserved NK cells
- Cash runway into mid-2024 following completion of
$103.5 million public offering in April 2022 - Conference call and webcast scheduled for June 1, 2022, at 8:30 a.m. EDT / 14:30 CET
HEIDELBERG, Germany, June 01, 2022 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed” or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today reported financial results for the first quarter ended March 31, 2022 and provided an update on clinical and corporate progress.
“We are excited about the progress we are making advancing our Innate Cell Engagers (ICE®) including completing enrollment of REDIRECT, our first registration directed study, and establishing a compelling proof of concept for AFM13 combined with NK cells as evidenced by the remarkable clinical data presented at AACR. These results continue to validate our three-pronged development approach and the potential of our ICE® molecules to offer novel treatments for heavily pretreated, relapsed/refractory patients with limited options,” said Dr. Adi Hoess, CEO of Affimed. “Our strong financial position allows us to maintain our focus on execution so that we can bring these important therapies to patients who need them as soon as possible.”
Clinical Stage Program Updates
AFM13 (CD30/CD16A)
- Affimed completed enrollment of its REDIRECT study (AFM13-202). The Company expects to report top-line data in the fourth quarter of 2022. REDIRECT is a phase 2, registration-directed study of AFM13 monotherapy in patients with relapsed or refractory CD30-positive peripheral T-cell lymphoma (PTCL).
- At an AACR 2022 Clinical Trials Plenary Session, Dr. Yago Nieto, M.D., Ph.D., Professor of Stem Cell Transplantation and Cellular Therapy at MD Anderson, presented follow-up data to the investigator sponsored trial (IST) (AFM13-104) investigating the combination of AFM13 pre-complexed with cord blood-derived natural killer cells followed by AFM13 monotherapy in relapsed/refractory CD30+ lymphomas. The treatment resulted in a
100% ORR with 8/13 (62% ) patients achieving a complete response after two cycles of treatment at the RP2D.
Durability data presented at AACR for patients treated at the RP2D was also promising. As of the cutoff date, of the eight patients who achieved a CR, seven remained in CR at median follow-up of 6.5 months, including two patients who remained in response after 10 months and two who received a consolidation autologous stem cell transplant (SCT).
The safety profile was well managed, with the main treatment related side-effect being infusion related reactions. The investigators did not observe any cases of cytokine release syndrome (CRS), neurotoxicity or graft versus host disease often associated with T-cell therapies. In general, side effects observed in the trial were transient and did not lead to treatment delays or discontinuation.
The recently approved amendment to the AFM13-104 trial protocol allows for an increase in the number of CD30-positive lymphoma patients treated at the RP2D to 40 - including Hodgkin and non-Hodgkin’s lymphoma patients. Furthermore, under the amended protocol, patients can receive more than two cycles of treatment.
The Company and MD Anderson expect to report updates on the study at a medical conference in the second half of the 2022.
AFM24 (EGFR/CD16A)
- In the monotherapy phase 1/2a clinical trial (AFM24-101), enrollment in cohort seven of the dose escalation study, which treated patients at the 720mg dose, was completed without dose limiting toxicities. Based on the pharmacokinetic and pharmacodynamic data, and in agreement with the Safety Review Committee (SRC), no further dose escalation is planned. The data confirm the selection of 480mg as the RP2D.
The Company is continuing enrollment in the expansion phase of the monotherapy study at the RP2D. The expansion cohorts include patients with renal cell carcinoma (clear cell), non-small cell lung cancer (EFGR mutant), and colorectal cancer.
- Enrollment continues in the phase 1/2a combination study of AFM24 with the anti-PD-L1 checkpoint inhibitor atezolizumab (Tecentriq®) (AFM24-102) to treat patients with non-small cell lung cancer (EGFR wildtype), gastric and gastroesophageal junction adenocarcinoma and pancreatic/hepatocellular/biliary tract cancer.
- Enrollment continues in the phase 1/2a combination study of AFM24 with the SNK01 (ex vivo expanded and activated autologous NK cell therapy from NKGen Biotech) cells (AFM24-103) to treat patients with non-small cell lung cancer (NSCLC, EGFR-wildtype), squamous cell carcinoma of the head and neck, and colorectal cancer.
- In these studies, the Company is evaluating the safety and efficacy of AFM24 in nine indication-specific cohorts, with a particular focus on NSCLC, which is represented in all three studies, and CRC, represented in two of the three studies. Affimed expects to report initial data from the studies in the second half of 2022.
- Presented a poster at AACR 2022 including data from dose escalation phase of AFM24-101, highlighting data that informed the selection of 480mg as the RP2D. Presented a poster at NK2022 conference featuring an analysis of the longitudinal effects of AFM24 in patients treated in AFM24-101, confirming the mechanism of action of AFM24 on the innate immune system.
Preclinical Programs
AFM28 (CD123/CD16A)
- AFM28 is a bispecific, tetravalent ICE® that targets CD16A on NK cells and macrophages, and CD123 on leukemic blasts and leukemic stem cells that are prevalent in acute myeloid leukemia (AML).
- The Company expects to submit an IND in June and is planning to start clinical investigation of AFM28 in the second half of 2022.
- At the NK2022 conference, the Company presented preclinical data demonstrating that AFM28 exhibits greater cell surface retention on NK cells than conventional monoclonal antibodies. Furthermore, AFM28 induced lysis of CD123-positive tumor cells when pre-complexed or when co-administered with cryopreserved NK cells, suggesting that AFM28 in combination with NK cells maintains anti-tumor activity, an exciting finding in that it presents the promise for an off-the-shelf therapy targeting leukemic blasts and LSCs in patients with AML.
Preclinical Pipeline
- Affimed is continuing the generation of several novel ICE® molecules derived from its proprietary ROCK® platform.
Partnerships and Collaborations
- The Company continues to advance its work with existing partners including MD Anderson, Artiva, and NKGen Biotech to ensure access to an off-the-shelf, cryopreserved NK cell for further development with its ICE® molecules and expects to provide updates on its NK cell development strategy in the second half of 2022.
- Partnered programs with both Genentech and Roivant continue to progress according to plan, and Affimed is eligible for additional proceeds from meeting pre-clinical and early regulatory achievement milestones.
First Quarter 2022 Financial Highlights
Affimed’s consolidated financial statements are prepared in accordance with IFRS as issued by the International Accounting Standard Board (IASB). The consolidated financial statements are presented in euros, the Company’s functional and presentation currency.
As of March 31, 2022, cash and cash equivalents totaled
Based on the Company’s current operating plan and assumptions, cash and cash equivalents, including proceeds from the April 2022 public offering, are expected to support operations into mid-2024.
Net cash used in operating activities for the quarter ended March 31, 2022, was
Total revenue for the quarter ended March 31, 2022, was
Research and development expenses for the quarter ended March 31, 2022, increased by
General and administrative expenses increased
Net finance income for the quarter ended March 31, 2022, decreased by
Net loss for the quarter ended March 31, 2022, was
The weighted number of common shares outstanding for the quarter ended March 31, 2022, was 123.4 million.
Additional information regarding these results is included in the notes to the consolidated financial statements as of March 31, 2022, which will be included in Affimed’s filings with the U.S. Securities and Exchange Commission (SEC).
Note on International Financial Reporting Standards (IFRS)
Affimed prepares and reports consolidated financial statements and financial information in accordance with IFRS as issued by the International Accounting Standards Board. None of the financial statements were prepared in accordance with Generally Accepted Accounting Principles in the United States. Affimed maintains its books and records in Euro.
Conference Call and Webcast Information
Affimed will host a conference call and webcast June 1, 2022, at 8:30 a.m. EDT / 14:30 CET to discuss first quarter 2022 financial results and corporate developments. The conference call will be available via phone and webcast.
To access the call, please dial +1 (409) 220-9054 for U.S. callers, or +44 (0) 8000 323836 for international callers, and reference passcode 4440407 approximately 15 minutes prior to the call.
A live audio webcast of the conference call will be available in the “Webcasts” section on the “Investors” page of the Affimed website at https://www.affimed.com/investors/webcasts-and-corporate-presentation/.
A replay of the webcast will be accessible at the same link for 30 days following the call.
About Affimed N.V.
Affimed (Nasdaq: AFMD) is a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer by actualizing the untapped potential of the innate immune system. The Company’s proprietary ROCK® platform enables a tumor-targeted approach to recognize and kill a range of hematologic and solid tumors, enabling a broad pipeline of wholly-owned and partnered single agent and combination therapy programs. The ROCK® platform predictably generates customized innate cell engager (ICE®) molecules, which use patients’ immune cells to destroy tumor cells. This innovative approach enabled Affimed to become the first company with a clinical-stage ICE®. Headquartered in Heidelberg, Germany, with offices in New York, NY, Affimed is led by an experienced team of biotechnology and pharmaceutical leaders united by a bold vision to stop cancer from ever derailing patients’ lives. For more about the Company’s people, pipeline and partners, please visit: www.affimed.com.
Forward-Looking Statements
This press release contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “goal,” “intend,” “look forward to,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “will,” “would” and similar expressions. Forward-looking statements appear in a number of places throughout this release and include statements regarding our intentions, beliefs, projections, outlook, analyses and current expectations concerning, among other things, the potential of AFM13, AFM24, AFM28 and our other product candidates, the value of our ROCK® platform, our ongoing and planned preclinical development and clinical trials, our collaborations and development of our products in combination with other therapies, the timing of and our ability to make regulatory filings and obtain and maintain regulatory approvals for our product candidates, our intellectual property position, our collaboration activities, our ability to develop commercial functions, clinical trial data, our results of operations, cash needs, financial condition, liquidity, prospects, future transactions, growth and strategies, the industry in which we operate, the trends that may affect the industry or us, impacts of the COVID-19 pandemic, the benefits to Affimed of orphan drug designation, the impact on our business by political events, war, terrorism, business interruptions and other geopolitical events and uncertainties, such as the Russia-Ukraine conflict and the risks, uncertainties and other factors described under the heading “Risk Factors” in Affimed’s filings with the SEC. Given these risks, uncertainties, and other factors, you should not place undue reliance on these forward-looking statements, and we assume no obligation to update these forward-looking statements, even if new information becomes available in the future.
Investor Relations Contact
Alexander Fudukidis
Director, Head of Investor Relations
E-Mail: a.fudukidis@affimed.com
Tel.: +1 (917) 436-8102
| Affimed N.V. | ||||||
| Unaudited consolidated statements of comprehensive income / (loss) | ||||||
| (in € thousand) | ||||||
| For the three months ended | ||||||
| March 31 | ||||||
| 2022 | 2021 | |||||
| Revenue | 8,006 | 11,659 | ||||
| Other income – net | 284 | 147 | ||||
| Research and development expenses | (18,379 | ) | (11,405 | ) | ||
| General and administrative expenses | (7,045 | ) | (4,486 | ) | ||
| Operating income / (loss) | (17,134 | ) | (4,085 | ) | ||
| Finance income / (costs) – net | 471 | 5,499 | ||||
| Income / (loss) before tax | (16,663 | ) | 1,414 | |||
| Income taxes | (2 | ) | (2 | ) | ||
| Income / (loss) for the period | (16,665 | ) | 1,412 | |||
| Other comprehensive income / (loss) | ||||||
| Items that will not be reclassified to profit or loss | ||||||
| Equity investments at fair value OCI - net change in fair value | (6,174 | ) | (1,253 | ) | ||
| Other comprehensive income / (loss) | (6,174 | ) | (1,253 | ) | ||
| Total comprehensive income / (loss) | (22,839 | ) | 159 | |||
| Basic and diluted earnings / (loss) per share in € per share | (0.14 | ) | 0.01 | |||
| (undiluted = diluted) | ||||||
| Weighted number of common shares outstanding | 123,444,217 | 116,204,455 | ||||
| Affimed N.V. | ||||||
| Consolidated statements of financial position | ||||||
| (in € thousand) | ||||||
| March 31, 2022 | December 31, 2021 | |||||
| (unaudited) | ||||||
| ASSETS | ||||||
| Non-current assets | ||||||
| Intangible assets | 1,580 | 1,607 | ||||
| Leasehold improvements and equipment | 3,754 | 3,814 | ||||
| Long-term financial assets | 6,174 | 12,348 | ||||
| Right-of-use assets | 813 | 972 | ||||
| 12,321 | 18,741 | |||||
| Current assets | ||||||
| Cash and cash equivalents | 169,850 | 197,630 | ||||
| Trade and other receivables | 4,547 | 4,809 | ||||
| Inventories | 485 | 421 | ||||
| Other assets and prepaid expenses | 6,048 | 3,534 | ||||
| 180,930 | 206,394 | |||||
| TOTAL ASSETS | 193,251 | 225,135 | ||||
| EQUITY AND LIABILITIES | ||||||
| Equity | ||||||
| Issued capital | 1,234 | 1,234 | ||||
| Capital reserves | 478,395 | 474,087 | ||||
| Fair value reserves | (12,147 | ) | (5,973 | ) | ||
| Accumulated deficit | (350,062 | ) | (333,397 | ) | ||
| Total equity | 117,420 | 135,951 | ||||
| Non-current liabilities | ||||||
| Borrowings | 15,713 | 17,060 | ||||
| Contract liabilities | 2,035 | 7,209 | ||||
| Lease liabilities | 288 | 368 | ||||
| Total non-current liabilities | 18,036 | 24,637 | ||||
| Current liabilities | ||||||
| Trade and other payables | 13,537 | 18,860 | ||||
| Borrowings | 2,039 | 580 | ||||
| Lease liabilities | 592 | 683 | ||||
| Contract liabilities | 41,627 | 44,424 | ||||
| Total current liabilities | 57,795 | 64,547 | ||||
| TOTAL EQUITY AND LIABILITIES | 193,251 | 225,135 | ||||
| Affimed N.V. | ||||||||||||||||||||
| Unaudited consolidated statements of cash flows (in € thousand) | ||||||||||||||||||||
| (in € thousand) | ||||||||||||||||||||
| For the three months ended | ||||||||||||||||||||
| March 31 | ||||||||||||||||||||
| 2022 | 2021 | |||||||||||||||||||
| Cash flow from operating activities | ||||||||||||||||||||
| Income / (loss) for the period | (16,665 | ) | 1,412 | |||||||||||||||||
| Adjustments for the period: | ||||||||||||||||||||
| - Income taxes | 2 | 2 | ||||||||||||||||||
| - Depreciation and amortization | 352 | 331 | ||||||||||||||||||
| - Share-based payments | 4,247 | 1,109 | ||||||||||||||||||
| - Finance income / costs – net | (471 | ) | (5,499 | ) | ||||||||||||||||
| (12,535 | ) | (2,645 | ) | |||||||||||||||||
| Change in trade and other receivables | 262 | (1,735 | ) | |||||||||||||||||
| Change in inventories | (64 | ) | (189 | ) | ||||||||||||||||
| Change in other assets and prepaid expenses | (2,435 | ) | 411 | |||||||||||||||||
| Change in trade, other payables, provisions and contract liabilities | (13,336 | ) | (11,822 | ) | ||||||||||||||||
| (28,108 | ) | (15,980 | ) | |||||||||||||||||
| Interest received | 27 | 0 | ||||||||||||||||||
| Paid interest | (337 | ) | (50 | ) | ||||||||||||||||
| Paid income tax | (2 | ) | (2 | ) | ||||||||||||||||
| Net cash used in operating activities | (28,420 | ) | (16,032 | ) | ||||||||||||||||
| Cash flow from investing activities | ||||||||||||||||||||
| Purchase of intangible assets | 0 | (4 | ) | |||||||||||||||||
| Purchase of leasehold improvements and equipment | (106 | ) | (962 | ) | ||||||||||||||||
| Net cash used for investing activities | (106 | ) | (966 | ) | ||||||||||||||||
| Cash flow from financing activities | ||||||||||||||||||||
| Proceeds from issue of common shares, including exercise of share-based payment awards | 61 | 101,860 | ||||||||||||||||||
| Transaction costs related to issue of common shares | (35 | ) | (6,350 | ) | ||||||||||||||||
| Proceeds from borrowings | 0 | 10,000 | ||||||||||||||||||
| Transaction costs related to borrowings | 0 | (201 | ) | |||||||||||||||||
| Repayment of lease liabilities | (172 | ) | (92 | ) | ||||||||||||||||
| Repayment of borrowings | (23 | ) | (23 | ) | ||||||||||||||||
| Cash flow from financing activities | (169 | ) | 105,194 | |||||||||||||||||
| Exchange rate related changes of cash and cash equivalents | 915 | 5,622 | ||||||||||||||||||
| Net changes to cash and cash equivalents | (28,695 | ) | 88,196 | |||||||||||||||||
| Cash and cash equivalents at the beginning of the period | 197,630 | 146,854 | ||||||||||||||||||
| Cash and cash equivalents at the end of the period | 169,850 | 240,672 | ||||||||||||||||||
| Affimed N.V. | |||||||||||||
| Unaudited consolidated statements of changes in equity | |||||||||||||
| (in € thousand) | |||||||||||||
| Issued capital | Capital reserves | Fair value reserves | Accumulated deficit | Total equity | |||||||||
| Balance as of January 1, 2021 | 983 | 345,164 | 1,720 | (275,874 | ) | 71,993 | |||||||
| Issue of common shares | 204 | 94,215 | 94,419 | ||||||||||
| Exercise of share-based payment awards | 3 | 1,156 | 1,159 | ||||||||||
| Equity-settled share-based payment awards | 1,109 | 1,109 | |||||||||||
| Income for the period | 1,412 | 1,412 | |||||||||||
| Other comprehensive loss | (1,253 | ) | (1,253 | ) | |||||||||
| Balance as of March 31, 2021 | 1,190 | 441,644 | 467 | (274,462 | ) | 168,839 | |||||||
| Balance as of January 1, 2022 | 1,234 | 474,087 | (5,973 | ) | (333,397 | ) | 135,951 | ||||||
| Exercise of share-based payment awards | 61 | 61 | |||||||||||
| Equity-settled share-based payment awards | 4,247 | 4,247 | |||||||||||
| Loss for the period | (16,665 | ) | (16,665 | ) | |||||||||
| Other comprehensive loss | (6,174 | ) | (6,174 | ) | |||||||||
| Balance as of March 31, 2022 | 1,234 | 478,395 | (12,147 | ) | (350,062 | ) | 117,420 | ||||||
FAQ
What are the latest results for AFM13 from Affimed?
When will Affimed report the topline data from the REDIRECT study?
What was Affimed's net loss for the first quarter of 2022?
How much cash does Affimed have after the public offering in April 2022?
What are the research and development expenses for Affimed in Q1 2022?
